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Background: Prophylaxis with unmethylated cytosine phosphate guanidine (CpG) oligodeoxynucleotides (ODN)
protects against several systemic experimental infections. Escherichia coli is a major cause of Gram-negative neonatal
bacterial meningitis and also causes meningitis and meningoencephalitis in older and immunocompromised
patients.
Methods: Wild-type (wt) and Toll-like receptor 9 (TLR9)-deficient mice were rendered neutropenic by intraperitoneal
administration of the anti-Ly-6G monoclonal antibody. Immunocompetent and neutropenic mice received
intraperitoneal CpG ODN or vehicle 72 h prior to induction of E. coli K1 meningoencephalitis.
Results: Pre-treatment with CpG ODN significantly increased survival of neutropenic wt mice from 33% to 75%
(P = 0.0003) but did not protect neutropenic TLR9-/- mice. The protective effect of CpG ODN was associated with an
enhanced production of interleukin (IL)-12/IL-23p40 with sustained increased levels in serum and spleen at least for
17 days after conditioning compared to buffer-treated animals. CpG-treated neutropenic wt mice showed reduced
bacterial concentrations and increased recruitment of Ly6ChighCCR2+ monocytes in brain and spleen 42 h after infection.
The levels of macrophage inflammatory protein 1α (MIP-1α) and interferon gamma (IFN-γ) in spleen were higher 42 h
after infection in CpG-treated compared to buffer-treated neutropenic animals. In immunocompetent mice, prophylaxis
with CpG ODN did not significantly increase survival compared to the buffer group (60% vs. 45%, P = 0.2).
Conclusions: These findings suggest that systemic administration of CpG ODN may help to prevent bacterial CNS
infections in immunocompromised individuals.
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Immunocompromised individuals, also the elderly, have
an increased risk of experiencing systemic and central
nervous system (CNS) infections [1,2]. In neutropenic pa-
tients, the causative agents of meningitis often are enteric
Gram-negative bacilli such as Escherichia coli that live in
the patient’s own digestive tract [3]. The ability of bacteria
to escape the host defense and achieve the threshold of* Correspondence: sandragottingen@gmail.com
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stated.bacteremia necessary for subsequent invasion of the brain
is probably higher in immunocompromised individuals
than in immunocompetent adults thus explaining the dif-
ferences in the occurrence of E. coli K1 meningitis [4].
Head trauma, neurosurgical interventions, or sepsis are
other risk factors for the development of E. coli meningi-
tis in adults either as a consequence of the impairment of
the local host defense or subsequent to direct inoculation
of bacteria into the CNS [5,6]. In immunodeficient and
older persons the efficacy of current vaccines is low [7].
Moreover, immunization efficacy probably decreases with
complex vaccination regimes against multiple pathogens.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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cause an infection in immunocompromised patients is an
unrealistic goal. Thus, it seems rational to pursue a con-
cept of pattern-specific stimulation of the innate immune
system with the goal of increasing resistance to infections
by several pathogens in the immunocompromised host.
Bacterial DNA containing unmethylated cytosine-
guanidine motifs linked by a phosphodiester (p) group
(CpG) activates mammalian lymphocytes and macro-
phages to produce cytokines including tumor necrosis
factor (TNF)-α, interleukin (IL)-6, IL-12, and interferon
gamma (IFN-γ), which are crucial for the immune response
to bacterial infections [8]. CpG oligodeoxynucleotides
(ODN) are short single-stranded DNA molecules which
contain unmethylated CpG motifs and mimic bacterial
DNA with immunostimulatory properties [9]. CpG-
containing motifs are considered pathogen-associated
molecular patterns (PAMPs) and are recognized by the
pattern recognition receptor (PRR) Toll-like receptor 9
(TLR9) [10]. We recently showed that stimulation of pri-
mary murine microglial cells with CpG ODN 1668 in-
creases phagocytosis and intracellular killing of E. coli K1,
an important pathogen for meningitis and meningo-
encephalitis [11,12]. In previous studies with experimental
animals, CpG ODN pre-treatment conferred protection
against a variety of bloodstream and other extracerebral
bacterial infections [13-20].
In this study, we investigated the protective properties
of CpG ODN 1668 pre-treatment in immunocompetent
mice as well as immunocompromised animals which
were depleted of granulocytes. To mimic infections after
cerebral/spinal trauma or surgery, murine meningo-
encephalitis was induced by direct injection of E. coli K1
into the CNS. Here, we report for the first time that CpG
ODN induces protection against a primary bacterial CNS
infection in neutropenic mice in a TLR9-dependent man-
ner but not in immunocompetent animals. CpG prophy-
laxis promoted bacterial clearance which correlated with
enhanced production of IL-12/IL-23p40, IFN-γ, and MIP-
1α, and increased recruitment of Ly6ChighCCR2+ mono-
cytes at early infection.Methods
Mice and monitoring
The animal experiments were approved by the Animal Care
Committee of the University Hospital of Göttingen and
by the Niedersächsische Landesamt für Verbraucherschutz
und Lebensmittelsicherheit (LAVES), Braunschweig, Lower
Saxony, Germany. C57Bl/6 wild-type (wt) (2 to 3 months
old, weight 20 to 30 g, Charles River Laboratory) and
TLR9-deficient animals on a C57Bl/6 background (2 to 5
months old, weight 20 to 32 g) were used in all experi-
ments [10]. Animals were weighed and scored daily (0, noapparent behavioral abnormality; 1, moderate lethargy; 2,
severe lethargy; 3, unable to walk; 4, dead) [21].
CpG ODN
In this study, we used CpG ODN 1668 (5′ TCC ATG
ACG TTC CTG ATG CT, molecular mass 6382.6 g/mol,
TIB Molbiol, Berlin, Germany) which has potent immu-
nostimulatory effects on primary cultures of microglial
cells [11,12]. CpG ODN 1668 is a phosphorothioate
(PTO) ODN that was dissolved in distilled water and
stored at -80°C. CpG ODN was administered intraperi-
toneally (ip) 3 days prior infection at a dose of 100 μg
per mouse in 200 μL phosphate buffered saline (PBS).
The buffer group received the same amount (34 μL) of
distilled water in 200 μL PBS. The use of a control CpG
ODN 1668 (5′ TCC ATG AGC TTC CTG ATG CT)
without immunostimulatory CpG motifs had no pro-
tective effect under the same experimental conditions
(data not shown).
Bacteria
The E. coli strain K1 (serotype O18:K1:H7) originally iso-
lated from the CSF of a child with neonatal meningitis
(gift of Dr. Gregor Zysk, Institute of Medical Microbiol-
ogy, Düsseldorf, Germany) was used in all experimental
infections [22]. Bacteria were grown overnight on blood
agar plates, harvested in 0.9% saline and stored at -80°C.
Frozen aliquots were used for the experiments and diluted
with saline to the required bacterial concentration.
Experimental design
The experimental design with neutropenic mice is sum-
marized in Figure 1A. Depletion of CD11b+Ly-6G+
Ly-6Cint neutrophils was achieved by ip injection of 50 μg
of anti-Ly6G monoclonal antibody (mAb, clone 1A8,
BioXcell, West Lebanon, NH, USA) [22]. Anti-Ly6G
mAb was administered daily starting 4 days before infec-
tion with a total of seven injections (from day -4 to day +2,
infection performed at day 0). Meningoencephalitis was
induced by injection of E. coli K1 into the superficial
right frontal neocortex of the anesthetized animals.
Neutropenic wt and TLR9−/− mice were inoculated with
1 × 104 colony forming units (CFU)/mouse while im-
munocompetent wt animals received 1 × 105 CFU/
mouse. In most of the survival experiments, animals
were monitored over a 14-day period after infection but
in one survival experiment, animals were observed for 2
months. In bacteriological studies, animals were sacri-
ficed 42 h after infection.
Sample processing
Serial blood samples were obtained by retro-orbital
punction at different time points for cyto/chemokine
measurement. Blood was collected, stored at 4°C for
Figure 1 CpG ODN protected neutropenic mice from E. coli meningoencephalitis. (A) Experimental design and impact of CpG ODN
pre-treatment (100 μg ip). (B) Survival and (C) clinical score of wt neutropenic mice. Survival of (D) TLR9-/- neutropenic and (E) immunocompetent
wt mice. Meningoencephalitis was induced by injection of 1 × 104 CFU E. coli K1. Kaplan-Meier curves were compared by log-rank test. Differences in
clinical scores between CpG- and buffer-treated mice were analyzed by Mann-Whitney U test (**P <0.01; ***P <0.001) and data are shown as
median ± 25th/75th percentiles.
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at 4°C. Serum was then transferred to another tube
and stored at -20°C until performance of the different
ELISAs. At end time point, animals were sacrificed by
cervical dislocation. Blood was obtained by intracar-
diac punction. The whole brain and spleen were re-
moved, and the cerebellum was dissected from the
brain stem. Half of the spleen and half of the cerebel-
lum were homogenized in 0.9% saline. Homogenates
were serially diluted in 0.9% saline and plated on
blood-agar plates (detection limit: 200 CFU/mL and
40 CFU/mL in cerebellar and spleen homogenates,
respectively).Flow cytometry
Anesthetized animals were perfused transcardially with
PBS 42 h after infection, and spleens and the right (inoc-
ulated) hemispheres were removed and processed. Brain
hemispheres were separately digested and homogenized
with collagenase D (2.5 mg/mL, Roche Diagnostics
GmbH, Mannheim, Germany) and DNase I (2 mg/mL,
Roche Diagnostics GmbH) using the gentle MACS dis-
sociator (Miltenyi Biotec, Germany). The resultant ho-
mogenates were mechanically dissociated and passed
through a 70-μm nylon cell strainer (BD Biosciences,
Franklin Lakes, NJ, USA). Leukocytes were separated by
a 37/70% Percoll gradient (GE Healthcare, Chalfont St
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ately passed through a 70-μm nylon strainer and proc-
essed as previously described [23]. Single cells were
stained with the following antibodies: CD45 (30-F11),
CD4 (RM4-5), CD27 (LG.3A10), CD11b (M1/70), and
Ly6C (HK1.4) purchased from BioLegend (San Diego,
CA, USA), CD3 (145-2C11), CD25 (PC61.5), CD19
(eBio1D3) NK1.1 (PK136), and FoxP3 (FJK-16 s) pro-
vided by eBioscience (San Diego, CA, USA), and Ly6G
(1A8, BD Pharmigen, Franklin Lakes, NJ, USA) and
CCR2 (FAB5538A, R&D Systems, Minneapolis, MN,
USA). At least 50,000 events were acquired on a FACS-
Canto II (BD Biosciences) and analyzed using FlowJo
software (version 8.8; Tree Star).
Cyto-/chemokine measurements
Levels of IL-12/IL-23p40, IL12p70, IFN-γ, and macro-
phage inflammatory protein 1α (MIP-1α) were determined
by DuoSet ELISA Development Kits (R&D Systems,
Wiesbaden, Germany) according to the manufacturer’s
instructions [24]. Cyto-/chemokines were measured in
cerebellar and splenic homogenates. Additionally, IL-12/
IL-23p40 was determined in serum samples collected at
different time points (52 h and 5 h before infection as well
as 42 h and 14 days after infection). The sensitivity was
7.5 pg/mL for all tested cyto-/chemokines. When mea-
surements were below the level of detection, a value of 7.4
was taken for statistical analysis.
Histological analysis
Paraffin-embedded, 2-μm coronal brain sections from
neutropenic mice sacrificed 42 h after infections were
analyzed. Chloroacetate esterase (CAE) stainings were
performed to evaluate the degree of inflammation in
three superficial meningeal regions and the hippocampal
fissure. Stained sections were blinded and semi-
quantitatively scored for the number of CAE-stained
leukocytes in one high-power field (×40 objective) per
region by a blinded investigator: no leukocytes (score 0),
<10 leukocytes (score 1), 10-50 leukocytes (score 2), >50
leukocytes (score 3). For each animal, the scores of the
individual fields were added and then divided by the
number of scored regions.
Statistical analysis
Survival was compared using the log-rank test. Differ-
ences between buffer- and CpG-treated groups were an-
alyzed by the Mann-Whitney U test and Fisher’s exact
test. Data are expressed as medians (25th/75th percen-
tiles). The correlation between bacterial titers and cyto-/
chemokine levels was analyzed using Spearman’s rank
correlation coefficient. For all analyses, GraphPad Prism
version 5 (GraphPad Software, San Diego, CA, USA)was used, and a P value <0.05 was considered statisti-
cally significant.
Results
CpG ODN protects neutropenic animals from E. coli
meningoencephalitis in a TLR9-dependent manner
A single intraperitoneal (ip) injection of 100 μg CpG
ODN 3 days before infection protected neutropenic wt
mice against intracerebral infection with E. coli K1
(Figure 1B). Survival at 14 days after infection was 75%
(27/36) in the CpG- versus 33% (11/33) in the buffer-
treated group (P = 0.0003; log-rank test). Accordingly,
buffer-treated animals exhibited more severe clinical
symptoms at 42 h and 45 h after infection than CpG-
treated mice (P ≤0.003; Mann-Whitney U test) (Figure 1C).
Neutropenic TLR9-/- mice were not protected from in-
tracerebral infection with 1 × 104 CFU E. coli K1 by pre-
treatment with 100 μg CpG ODN (P = 0.10, log-rank
test; survival 14 days after infection 8% (2/25, CpG
group) versus 36% (9/25, buffer group) (Figure 1D).
CpG ODN effect as a prophylactic agent against
meningoencephalitis in immunocompetent animals
Mice with an intact granulocyte function were less suscep-
tible to intracerebral E. coli K1 infection (LD50 = 6 ×
104 CFU) than mice which were depleted from circulating
neutrophils by mAb 1A8 administration (LD50 = 5 ×
103 CFU). The protection conferred by a single ip dose of
100 μg CpG ODN was mild in immunocompetent ani-
mals and failed to reach statistical significance (Figure 1E;
P = 0.2; log-rank test; survival 14 days after infection was
60% (12/20) in CpG ODN group versus 45% (9/20) in
the buffer group). Although the differences also were not
statistically significant (P = 0.09; Mann-Whitney U test),
buffer-treated animals tended to show a higher clinical
score than CpG-treated mice at the early phase of menin-
goencephalitis (42 h after infection).
Intraperitoneal administration of CpG ODN decreases
weight in uninfected wt mice but not in TLR9-deficient
mice
A sensitive indicator of sickness behavior of uninfected
neutropenic wt mice which received a single ip injection
of 100 μg CpG ODN (n = 46) was loss of weight [25].
Twenty-four hours after CpG ODN administration the
weight was 94.1% (92.9/95.2), whereas in immunocom-
promised control animals (n = 42) weight remained stable
at 101.3% (100.0/102.2) (P <0.0001; Mann-Whitney U
test). Uninfected immunocompetent mice (n = 20/group)
also lost weight after a single injection of 100 μg CpG
ODN: 24 h after CpG ODN administration the weight
was 95.7% (94.3/96.7%), whereas immunocompetent
buffer-treated animals did not lose weight (98.7% (97.0/
101.3%)) (P <0.0001; Mann-Whitney U test). Within the
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regained their pre-treatment weight. Conversely, the
weight of TLR9 deficient mice (n = 25/group) was not
influenced by the administration of CpG ODN (99.1%
(97.6/100.4)).
Pre-conditioning with CpG ODN decreases the bacterial
concentrations in cerebellar and spleen homogenates in
neutropenic wt mice at the early phase of infection
Neutropenic wt mice pre-conditioned with 100 μg CpG
ODN (n = 10) or treated with buffer solution (n = 9)
were sacrificed 42 h after infection to determine the pro-
tective effect of CpG ODN. The bacterial density in
cerebellum homogenates of CpG-treated mice was 2.54
(2.30/3.66) log10CFU/mL compared to 5.09 (3.47/6.84)
log10CFU/mL in buffer-treated mice (P = 0.01; Mann-
Whitney U test) (Figure 2A). The bacterial density in
the spleen in CpG-treated mice was 2.75 (1.59/4.90)
log10CFU/mL compared to 4.65 (4.30/5.92) log10CFU/
mL in buffer-treated animals (P = 0.04; Mann-Whitney
U test) (Figure 2B).
CpG-treated neutropenic animals that survived the
infection show a delay in the clearance of bacteria
After 14 days of infection, 45% (9/20) of the surviving
neutropenic wt animals pre-conditioned with CpG
ODN still showed positive bacterial cultures in cerebel-
lum homogenates versus 10% (1/10) of the buffer-
treated animals (Figure 3A, P = 0.08 by Mann-Whitney
U test; P = 0.10 by Fisher’s exact test). Positive cultures
in spleen homogenates were found in 20% (4/20) of
CpG-treated and in 20% (2/10) of buffer-treated ani-
mals (Figure 3B). We therefore performed a survival
experiment in which buffer and CpG-treated animals
(n = 9 mice/group) were infected with 1 × 104 CFU/
mouse and monitored for 2 months. Two months after
infection, the bacterial cultures in all surviving animals
(7/9 in the CpG- and 1/9 in the buffer-treated groups)Figure 2 CpG ODN pre-treatment decreased bacterial loads in the ea
Bacterial concentrations in (A) cerebellum and (B) spleen were determined
n = 9-10 mice/group. Horizontal bars indicate median values. Statistical anawere negative (level of detection: 200 CFU/mL and
40 CFU/mL in cerebellum and spleen homogenates,
respectively). In all survival experiments, no mortality
occurred later than day 6 after infection. All surviving
immunocompetent mice had negative bacterial cultures
in tissue homogenates 14 days after infection.
CpG ODN immunization increases the percentage of
inflammatory monocytes in the infected CNS and spleens
of neutropenic mice
Pre-treatment with CpG ODN can modify leukocyte
populations in infected tissues [26]. We therefore ana-
lyzed distinct cell types in the spleens and brains
(right hemisphere containing the site of injection) of
neutropenic mice at 42 h after E. coli K1 infection by
flow cytometry. The absolute and relative numbers of
the different cell subsets found in the CNS are
depicted in Table 1. Flow cytometry revealed absence
of CD11b+Ly6G+Ly6Cint neutrophils in spleen and
brain in all anti-Ly6G-treated mice (data not shown).
The percentage of inflammatory monocytes (CD45+
CD11b+Ly6ChighCCR2+) among CD45+ leukocytes was
significantly higher in CpG-treated mice (P = 0.035;
Mann-Whitney U test) while the total number of inflam-
matory monocytes/animal did not quite reach statistical
significance (P = 0.073; Mann-Whitney U test). The per-
centage of T cells (CD45+CD3+) and regulatory T cells
(CD45+ CD4+CD3+CD25+FoxP3+) among CD45+ leuko-
cytes significantly decreased in the CNS of CpG-treated
animals (P ≤0.04; Mann-Whitney U test), while the per-
centage of NK cells (CD45+NK1.1+CD3-) remained un-
affected. The numbers and percentages of CD45+CD11b+
Ly6ChighCCR2-, CD45+CD11b+Ly6CintCCR2- monocytes
and CD45intCD11bintLy6C- microglial cells were compar-
able between CpG ODN- and buffer-treated animals.
In the spleen, pre-treatment with CpG ODN signifi-
cantly increased the percentage of inflammatory mono-
cytes among all leukocytes (P = 0.009; Mann-Whitney Urly phase of meningoencephalitis in neutropenic mice.
42 h after intracerebral E. coli K1 infection (1 × 104 CFU/mouse).
lysis was performed by Mann-Whitney U test.
Figure 3 CpG-treated neutropenic animals that survived the infection showed a delay in the clearance of bacteria. Bacterial
concentrations in (A) cerebellum and (B) spleen were determined 14 days after intracerebral E. coli K1 infection in those animals which survived
the infection (n = 10-20 mice/group). Horizontal bars indicate median values. Statistical analysis was performed by Mann-Whitney U test.
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ages of T cells and regulatory T cells among all CD45+
cell population were significantly decreased in the
spleens (P ≤0.009; Mann-Whitney U test) of infected
CpG-treated mice compared to buffer-treated animals.
The percentage of NK cells was not influenced by pre-
treatment with CpG ODN.
Cyto-/chemokine response to CpG ODN treatment in
neutropenic infected mice
We determined the effects of CpG pre-treatment on the
production of IL-12 and IFN-γ as Th1-related cytokines
[13-15,18-20]. We also measured MIP-1α levels since an
increased production was observed after intragastric and
intratracheal administration of CpG ODN [26,27]. In
neutropenic wt mice (n = 9-10/group), IL-12/IL-23p40,
IL-12p70, IFN-γ, and MIP-1α levels were measured 42 h
after infection (Figures 4 and 5). Concentrations of
IL12p70 were low in both groups with median values
ranging from 7.5 to 11 pg/mL (data not shown). Animals
that were pre-conditioned with CpG ODN showed in-
creased levels of IFN-γ (P = 0.0009; Mann-Whitney UTable 1 Subpopulations of T cells in the CNS of CpG- and buf
Absolute no. of c
CpG
CD45+ cells 237427 (122770/25
T cells (CD45+CD3+) 4274 (3560/4607)
Regulatory T cells CD45+CD4+CD3+CD25+FoxP3+ 172 (122/307)
NK cells CD45+NK1.1+CD3- 3631 (3138/7180)
Inflammatory monocytes CD45+CD11b+Ly6ChighCCR2+ 66905 (46994/1013
Monocytes CD45+CD11b+Ly6ChighCCR2- 13798 (6089/22579
Monocytes CD45+CD11b+Ly6CintCCR2- 40918 (15076/6949
Microglia CD45intCD11bintLy6C- 6392 (4150/27330)
aData are medians (25th/75th percentiles) determined by forward and side-scatter p
separate experiments.
bSignificantly different (P <0.05) vs. buffer-treated group (Mann-Whitney U test).test) and IL-12/IL-23p40 (P = 0.0006; Mann-Whitney U
test) in spleen and higher levels of MIP-1α in both cere-
bellum (P = 0.09; Mann-Whitney U test) and spleen
(P = 0.004; Mann- Whitney U test) compared to buffer-
treated mice (Figure 4). IFN-γ and IL-12/IL-23p40 con-
centrations in cerebellum homogenates were similar in
both groups. A four- to six-fold increase of serum IL-12/
IL-23p40 levels was found after the administration of a
single ip injection of 100 μg CpG ODN in mice at 52
and 5 h before infection (Figures 5A and B). The in-
creased IL-12/IL-23p40 levels in serum of CpG-treated
mice persisted until 42 h (Figure 5C).
Fourteen days after infection (Figure 6), surviving neu-
tropenic wt animals pre-conditioned with CpG ODN
(n = 20) showed higher levels of MIP-1α in both cere-
bellum (P = 0.09; Mann-Whitney U test) and spleen
(P = 0.04; Mann-Whitney U test) and increased levels of
IL-12/IL-23p40 in spleen (P = 0.0007; Mann-Whitney U
test) and serum (P = 0.004; Mann- Whitney U test) com-
pared to buffer-treated mice (n = 10). Levels of IL-12/IL-
23p40 in cerebellum homogenates were comparable in
both groups. To examine whether increased levels offer-treated neutropenic mice 42 h after infection
ellsa Percent among all CD45+ cellsa
Buffer CpG Buffer
7348) 228016 (169274/314119)
4844 (3065/8602) 2 (1.8/2.9)b 3.2 (2.8/3.6)
375 (167/489) 0.08 (0.06/0.13)b 0.2 (0.12/0.55)
2588 (1882/6996) 2.6 (1.6/3) 2.2 (1.5/3.6)
06) 40683 (23199/55803) 39.4 (27.6/46.9)b 25.9 (23.3/28.9)
) 13150 (7054/24206) 7 (4.9/11) 8.54 (5/11.7)
9) 39167 (19894/65079) 22 (15.9/27.51) 26.4 (17.35/34)
5316 (2869/18381) 3.56 (2.6/10.62) 4.69 (2.48/7.71)
roperties from the right hemisphere of animals (n = 6-7/group) of at least three
Figure 4 Prophylaxis with CpG ODN significantly increased IFN-γ, IL-12/IL-23p40, and MIP-1α in spleen homogenates at early infection.
(A, D) IFN-γ, (B, E) IL-12/IL-23p40, and (C, F) MIP-1α were measured 42 h after intracerebral E. coli K1 infection. Each symbol represents an
individual neutropenic mouse (n = 9-10/group). Horizontal bars indicate median values. Statistical analysis was performed by Mann-Whitney U test.
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tures in cerebellum homogenates of CpG-treated mice
(n = 20 mice) that survived 2 weeks after infection, the
Spearman correlation rank test was performed. The cor-
relation coefficients (rs) were +0.08 (P = 0.73) for IL-12/
IL-23p40 and -0.23 (P = 0.33) for MIP-1α concentrations.
Characterization of the meningeal inflammation after
E. coli K1 challenge
Meningeal inflammation scores from CAE stainings of
neutropenic wild-type animals which were sacrificed
42 h after infection are presented in Figure 7. CAE stain-
ing confirmed the low amount of infiltrating leukocytes
as previously reported [22] and showed no differences
between scores in CpG- and buffer-treated animals
(median 0.43 (0.16/0.68) versus 0.65 (0.16/1.29), P = 0.5).Figure 5 Protective effect of CpG ODN pre-treatment correlated with
buffer was administered 72 h before infection. IL-12/IL-23p40 levels (in pg/
at the time of sacrifice, that is, 42 h after intracerebral E. coli K1 infection (1
mouse (n = 9-10/group). Horizontal bars indicate median values. StatisticalDiscussion
The concept of increasing the resistance against several
bacterial infections upon systemic stimulation with one
immune activator has been pursued for decades, with
mixed success. In rodent models, CpG ODN convey
protection against a variety of bloodstream and other
extracerebral infections induced by intraperitoneal injec-
tion of Francisella tularensis [14], Listeria monocytogenes
[17] and Burkholderia pseudomallei [20], oral infection
of neonates with Cryptosporidium parvum [13], intrana-
sal/intraperitoneal injection of Yersinia pestis [16], intra-
tracheal challenge with Cryptococcus neoformans [18],
against experimental malaria elicited by intravenous in-
jection of Plasmodium yoelii [15] and polymicrobial sep-
sis induced by the colon ascendens stent peritonitis
procedure [19].high concentrations of IL-12/IL-23p40 in serum. CpG ODN or
mL) were measured at (A) 52 h and (B) 5 h before infection and (C)
× 104 CFU/mouse). Each symbol represents an individual neutropenic
analysis was performed by Mann-Whitney U test.
Figure 6 Survival upon CpG ODN pre-treatment correlated with high levels of IL-12/IL-23p40 and MIP-1α. Cyto-/chemokine concentrations in
(A, B) cerebellar and (C, D) spleen homogenates and (E) serum from CpG- (n = 20) and buffer-treated (n = 10) mice were measured 14 days after
intracerebral E. coli K1 infection. Each symbol represents an individual neutropenic mouse. Horizontal bars indicate median values.
Statistical analysis was performed by Mann-Whitney U test.
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Ly6G+Ly6Cint neutrophils as a model of the immuno-
compromised host to investigate the capacity of CpG
ODN to strengthen the local immune response for a suc-
cessful elimination of bacteria injected directly into the
brain. We were able to show for the first time that sys-
temic immunostimulation with CpG ODN not only pro-
tects against systemic bacterial infections but also against
an intracerebral challenge with E. coli. The CpG motifFigure 7 Meningeal infiltration score was similar in CpG- and
buffer-treated animals. Meningeal infiltration score was calculated
in chloroacetate esterase-stained brain sections of CpG- and
buffer-treated neutropenic wt mice which were sacrificed 42 h after
induction of E. coli meninigoencephalitis. Each symbol represents an
individual mouse. Bars indicate median values. Statistical analysis was
performed by Mann-Whitney U test.evaluated in this work stimulated microglial cells and in-
creased their ability to phagoytose and destroy E. coli
strains intracellularly [11]. Prophylactic intraperitoneal
administration of 100 μg of this CpG motif 3 days before
intracerebral inoculation of E. coli increased the number
of neutropenic mice surviving the infection. By observing
the time course of the clinical symptoms we assumed
that CpG administration increased the local resistance of
the brain against infection: only animals which did not
develop clinical symptoms (clinical score >1, severe leth-
argy), survived. Once the infection had spread and caused
clinical symptoms, the ultimate outcome was fatal.
Prophylaxis with CpG ODN did not prolong the interval
from infection to death (median: 43 h for CpG- and
buffer-treated neutropenic mice) suggesting a moderate
contribution of the systemic inflammatory response
which mainly influences the later course of the infection.
The lack of protection in TLR9-deficient neutropenic
mice strongly suggests that CpG ODN mediated protec-
tion by stimulation of TLR9 and not by any other non-
specific immunomodulatory effect. Among the animals
that survived 14 days after infection, 45% of the CpG-
treated mice showed positive bacterial cultures in cere-
bellum compared to 10% of buffer-treated animals
(P = 0.08; Mann-Whitney U test). No mouse died later
than 6 days after infection. To confirm that CpG-treated
animals which were alive after 14 days were able to com-
pletely control bacterial growth, one of the survival experi-
ments was extended for a period of 2 months. After 2
months, all surviving CpG pre-conditioned animals had
cleared bacteria from brain and spleen. In 2-week sur-
vival studies using immunocompetent wt mice, CpG
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group by only 15% (P = 0.2) with no positive cultures in
homogenates at the end of the experiment.
In correlation with the enhanced survival, CpG ODN
administration significantly reduced bacterial loads in
spleen homogenates, an indicator of bacteremia, 42 h
after infection. Similarly, bacterial burdens in cerebellum
were signicantly lower in mice pre-conditioned with
CpG ODN compared to buffer-treated neutropenic ani-
mals. However, the meningeal inflammation scores were
comparable in both groups. To identify the possible
mechanisms behind the CpG-induced protection in our
neutropenic mice, we investigated the pattern of cyto-
kine/chemokine production. Because resistance to in-
fections upon CpG ODN pre-conditioning has been
related to the promotion of T helper 1 (Th1) responses
[13-15,18-20], we focused on IL12 and IFN-γ. IL-12p40
is produced primarily by activated inflammatory cells in-
cluding monocytes/macrophages, neutrophils, microglia,
and dendritic cells (DCs) in response to pathogens medi-
ated by PRRs such as TLRs [28]. IL-12p40 associates
with the p35 chain to form IL-12p70, but also with a
p19 chain to form IL-23 [29]. In the present study, ad-
ministration of CpG ODN caused a six-fold increase in
serum IL-12/IL-23p40 levels at 52 h before infection.
The elevated levels of IL-12/IL-23p40 in serum persisted
for at least 17 days after CpG ODN prophylaxis (median:
313 pg/mL in CpG ODN vs. 192 pg/mL in buffer-treated
mice at 14 days after infection). Correspondingly, CpG-
treated animals showed an increased concentration of
IL-12/IL-23p40 in spleen homogenates at 42 h, and
these high levels were maintained until 14 days after in-
fection. CpG-preconditioned animals showed increased
levels of IFN-γ in spleen homogenates compared to the
buffer group at 42 h after infection. CpG DNA induces
the production of IL-12 that promotes IFN-γ secretion
by NK cells [30]. We did not observe differences in the
number of NK cells between the CpG and buffer-treated
groups at 42 h after infection.
Pre-treatment with CpG ODN induced the recruit-
ment of leukocytes to lung tissue and gastric mucosa in
healthy and infected mice [16,27]. In the absence of
functional CD11b+Ly6G+Ly6Cint neutrophils, our CpG-
treated mice controlled bacterial growth by recruiting
higher percentages of Ly6ChighCCR2+ monocytes in both
spleen and brain than buffer-treated animals. CpG pre-
conditioning also decreased the percentage of CD45+
CD4+CD3+CD25+FoxP3+ regulatory T cells in spleen
and brain 42 h after infection. Similarly, during acute in-
fection with Toxoplasma gondii and Listeria monocyto-
genes a transient loss of Treg cells caused by IL-2
insufficiency was essential for initiation of Th1 responses
and host protection against infection [31]. Furthermore,
CpG ODN 2006 downregulated the proportion of Tregcells in peripheral blood mononuclear cells from patients
with non-small cell lung cancer [32].
Chemokines are key players in leukocyte recruitment
by endothelial cells upon infection. In patients with bac-
terial meningitis, CSF levels of chemokines including
MIP-1α are elevated [33]. Chemokines can be released
into the CSF by different cell populations, including
microglial cells, resident macrophages and migrating
leukocytes depending on the stage of disease [34]. MIP-
1α release in human brain microvessel endothelial cells
is negligible under physiological conditions but can be
upregulated after stimulation with IL-1β or LPS [35].
We found higher levels of MIP-1α in both cerebellum
and spleen homogenates of CpG-treated infected ani-
mals compared to infected control mice. Peak MIP-1α
spleen concentrations were found at 42 h but the levels
were elevated until 14 days after infection. We recently re-
ported a strong correlation between E. coli K1 loads and
increased levels of IL-1β, IL-6, KC (rodent homologue of
growth-related oncogene-α/CXCL1), and macrophage in-
flammatory protein 2 (MIP-2/CXCL2) in cerebellum ho-
mogenates of untreated neutropenic wt animals [22]. In
the current work, we did not find a significant correlation
between the bacterial burdens and the levels of MIP-1α
and IL-12/IL-23p40 in cerebellum homogenates of CpG-
treated mice that survived 2 weeks after E. coli challenge.
The administration of CpG ODN caused weight loss
even in uninfected mice. This weight loss was absent in
neutropenic TLR9-deficient mice, suggesting that it cor-
responds to a CpG ODN-induced sickness behavior [25]
which has been observed in animal and clinical studies
[36-38]. In vitro, exposure of co-cultures of neurons with
microglial cells to CpG ODN caused neuronal injury,
which often started with the attack of microglial cells on
axons [39]. In this study, CpG ODN strongly increased
survival in spite of the initial weight loss induced by the
CpG ODN treatment.
Conclusions
An intraperitoneal injection of CpG ODN protected neu-
tropenic mice against intracerebral infection with E. coli
K1 by recruiting higher amounts of inflammatory mono-
cytes into the CNS, decreasing bacterial burdens in the
cerebellum and reducing the degree of bacteremia. There-
fore, CpG ODN activated the innate immune response
not only by influencing the activity of phagocytes of the
peritoneum and with direct contact to the circulation, but
also those situated in deep compartments such as the
CNS. By this way, the systemic administration of CpG
ODN may help to prevent CNS infections in immuno-
compromised individuals even after direct inoculation of
bacteria into the intracranial compartments which can
occur with open head trauma and after surgery, including
placement of an external ventricular drain. Supporting our
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addition of CpG to low doses of anti-CTLA-4 and anti-
OX40 (two antibodies directed against surface markers of
tumor-specific Treg cells) injected locally in a peripheral
tumor site in the rat expanded anti-tumor responses to
distant tumor sites including the brain [40]. The use of
CpG DNA in vaccinations offers several advantages [41]:
(1) it can be synthesized with high purity; (2) CpG motifs
can exert their immunostimulatory effects either as part
of a vaccine or when delivered alone; (3) the presence of
CpG motifs contributes to DNA vaccination success rates
[42,43]; and (4) Th1 adjuvant properties of CpG DNA en-
able successful immunization in neonates who are difficult
to immunize because of their immature innate immune
system [44]. In accordance with this concept, Soogard and
collaborators reported the improvement of the immuno-
genicity of the 7-valent pneumococcal conjugated vaccine
in HIV-infected adults by the addition of a variant of CpG
(CPG 7909, Coley Pharmaceutical Group) [45]. For these
reasons, we suggest conducting a clinical trial with CpG
ODN in immunocompromised patients with a high risk of
CNS infections.
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